Clinical Trials Logo

Differentiated Thyroid Cancer clinical trials

View clinical trials related to Differentiated Thyroid Cancer.

Filter by:
  • Approved for marketing  
  • Page 1

NCT ID: NCT02211222 Approved for marketing - Clinical trials for Differentiated Thyroid Cancer

An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer

Start date: n/a
Phase: N/A
Study type: Expanded Access

This Expanded Access Program (EAP) consists of a Prerandomization Phase and a Randomization Phase. Only subjects with radioiodine-refractory DTC who fulfill the eligibility criteria will be treated. These subjects will be treated until progression of disease or unacceptable toxicity.